Estimation of Oncologic Surgery Case Volume Before and After the COVID-19 Pandemic in France
- PMID: 36701152
- PMCID: PMC9880797
- DOI: 10.1001/jamanetworkopen.2022.53204
Estimation of Oncologic Surgery Case Volume Before and After the COVID-19 Pandemic in France
Abstract
Importance: COVID-19 has had a major effect on health care activities, especially surgery. At first, comparisons were proposed using 2019 activities as the highest standard. However, while such an approach might have been suitable during the first months of the pandemic, this might no longer be the case for a longer period.
Objective: To examine approaches that may better assess the use of cancer surgeries.
Design, setting, and participants: In a cross-sectional design, the nationwide French hospital facility data (Medicalised Information System Program) were used to assess cancer surgery for 6 cancer site categories in adults from January 1, 2010, to December 31, 2021.
Exposure: Estimated cancer surgery activity during the COVID-19 pandemic.
Main outcomes and measures: Three models were proposed to assess the expected number of surgical procedures between 2020 and 2021 and make a comparison with those observed in earlier years.
Results: In France, cancer removal surgeries account for approximately 7000 hospitalizations per year for liver cancer; 4000 for pancreatic cancer; 7700 for ovarian cancer; 1300 for esophagus cancer; 23 000 for ear, nose, and throat (ENT) cancer; 78 000 for breast cancer; and 16 600 for thoracic cancers. For most cancer sites, the number of surgical procedures increased from 2010 to 2019: liver, 14%; pancreas, 38%; ovary, 14%; esophagus, 18%; breast, 8%; and thoracic, 29%. Assuming stability, these values underestimate the gap in activity observed in 2020-2021. For other procedures, a decrease was observed: stomach, -10%, and ENT, -6%. Assuming stability, these values overestimate the gap in activity observed in 2020-2021. At the end of 2021, according to the model, the gap in activity observed in 2020-2021 was estimated at between -1.4% and 1.7% for breast, -6.6% and -7.3% for thoracic, -3.1% and -2.5% for ovarian, -4.2% and -1.7% for pancreas, -6.7% and 5.9% for stomach, and -13.0% and -13.9% for esophageal cancers. For ENT, liver, and urologic cancers, because the trend was different before and after 2015, it was necessary to opt for modeling using only the most recent period. The cumulative gap in activity observed in 2020-2021 was estimated at -1.0% for ENT cancers, -5.3% for liver cancers, and -2.9% for urologic cancers.
Conclusions and relevance: The findings of this study suggest that short- and medium-term trends must be considered to estimate COVID-19 cancer surgery activities. Breast cancer is the site for which the activity showed the smallest decrease during the pandemic, with almost full recovery in 2021.
Conflict of interest statement
Figures
![Figure 1.](https://cdn.statically.io/img/www.ncbi.nlm.nih.gov/pmc/articles/instance/9880797/bin/jamanetwopen-e2253204-g001.gif)
![Figure 2.](https://cdn.statically.io/img/www.ncbi.nlm.nih.gov/pmc/articles/instance/9880797/bin/jamanetwopen-e2253204-g002.gif)
Similar articles
-
Undiagnosed Cancer Cases in the US During the First 10 Months of the COVID-19 Pandemic.JAMA Oncol. 2024 Apr 1;10(4):500-507. doi: 10.1001/jamaoncol.2023.6969. JAMA Oncol. 2024. PMID: 38386344 Free PMC article.
-
New Cancer Diagnoses Before and During the COVID-19 Pandemic.JAMA Netw Open. 2023 Sep 5;6(9):e2332363. doi: 10.1001/jamanetworkopen.2023.32363. JAMA Netw Open. 2023. PMID: 37669049 Free PMC article.
-
The impact of the COVID-19 coronavirus pandemic on the surgical management of gynecological cancers: Analysis of the multicenter database of the French SCGP and the FRANCOGYN group.J Gynecol Obstet Hum Reprod. 2021 Oct;50(8):102133. doi: 10.1016/j.jogoh.2021.102133. Epub 2021 Mar 28. J Gynecol Obstet Hum Reprod. 2021. PMID: 33789183 Free PMC article.
-
Forecasting the Future of Urology Practice: A Comprehensive Review of the Recommendations by International and European Associations on Priority Procedures During the COVID-19 Pandemic.Eur Urol Focus. 2020 Sep 15;6(5):1032-1048. doi: 10.1016/j.euf.2020.05.007. Epub 2020 May 31. Eur Urol Focus. 2020. PMID: 32553544 Free PMC article. Review.
-
[Volume and health outcomes: evidence from systematic reviews and from evaluation of Italian hospital data].Epidemiol Prev. 2013 Mar-Jun;37(2-3 Suppl 2):1-100. Epidemiol Prev. 2013. PMID: 23851286 Review. Italian.
Cited by
-
Did the COVID-19 pandemic delay treatment for localized breast cancer patients? A multicenter study.PLoS One. 2024 May 31;19(5):e0304556. doi: 10.1371/journal.pone.0304556. eCollection 2024. PLoS One. 2024. PMID: 38820299 Free PMC article.
-
Volume and Practice-Setting Shift of Laryngology Procedures During the COVID-19 Pandemic: A Reg-ENT Database Analysis.OTO Open. 2024 Apr 8;8(2):e128. doi: 10.1002/oto2.128. eCollection 2024 Apr-Jun. OTO Open. 2024. PMID: 38590586 Free PMC article.
-
Impact of the COVID-19 pandemic on clinical presentation, treatments, and outcomes of new breast cancer patients: A retrospective multicenter cohort study.Cancer Med. 2023 Nov;12(22):20918-20929. doi: 10.1002/cam4.6637. Epub 2023 Nov 1. Cancer Med. 2023. PMID: 37909210 Free PMC article.
References
MeSH terms
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous